Cited by 941Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychotherapy Techniques and Applications

The DOI matches its Crossref record; 153 of the 159 references it cites were found in a registry or an index.

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability

Anderson, Ian M.·2000·Journal of Affective Disorders

DOI 10.1016/s0165-0327(99)00092-0

Open this paper in CoChat — free account

Abstract

Background A meta-analysis of the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) against tricyclic antidepressants (TCAs) in depressed patients was carried out. Methods Efficacy data from 102 randomised controlled trials (10706 patients) were pooled to provide a summary variance-weighted effect size. Tolerability data from 95 studies (10553 patients) were combined to give variance-weighted relative risk of drop out for all reasons and for adverse effects from each study. The effect of age, treatment setting, severity and TCA dose were examined as well as the performance of individual SSRIs and TCAs where there were sufficient studies. Results There is no overall difference in efficacy between SSRIs and TCAs (effect size -0.03, 95% confidence interval -0.09 to 0.03). TCAs do appear more effective in in-patients (-0.23, -0.40 to -0.05) and amitriptyline is more effective than SSRI comparators (-0.14, -0.25 to -0.03) but publication bias cannot be excluded. The SSRIs are better tolerated, with significantly lower rates of treatment discontinuations overall (relative risk 0.88, 0.83 to 0.93; number needed to treat 26) and due to side effects (0.73, 0.67 to 0.80; number needed to treat 33). Individual SSRIs show a similar advantage except for fluvoxamine which does not differ from the TCAs. Individual TCAs show a similar disadvantage in tolerability compared to SSRIs except for dothiepin against which SSRI treatment results in more side-effect related…

Integrity signals

Registry

Crossref · 10.1016/s0165-0327(99)00092-0

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Book Reviews: Statistical Methods for Meta-Analysis Larry V. Hedges and Ingram Olkin New York: Academic Press, 1985. xxii + 369 pp
Wasserman, S. S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,377
Research Diagnostic Criteria
Spitzer, R. L. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770300115013 · Cited by 6,946
Diagnostic criteria for use in psychiatric research.
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G., & Munoz, R. A. (1972) · Archives of General Psychiatry · doi:10.1001/archpsyc.1972.01750190059011 · Cited by 5,491
Statistical Methods for Meta-Analysis.
Freeman, P. R., Hedges, L. V., & Olkin, I. (1986) · Biometrics · doi:10.2307/2531069 · Cited by 4,840
Research Diagnostic Criteria
Spitzer, R. L., Endicott, J., & Robins, E. (1978) · PsycTESTS Dataset · doi:10.1037/t04137-000 · Cited by 556
Recognition and management of depression in general practice: consensus statement
Paykel, E. S., & Priest, R. G. (1992) · BMJ · doi:10.1136/bmj.305.6863.1198 · Cited by 540
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.
Song, F., Freemantle, N., Sheldon, T. A., House, A., Watson, P., Long, A., & Mason, J. (1993) · BMJ · doi:10.1136/bmj.306.6879.683 · Cited by 399
Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
Danish University Antidepressant Group (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90081-i · Cited by 398

Show all 159 references

Research works printed but not linked: 14

Amin, 1984, Fluvoxamine: antidepressant effects confirmed in a placebo-controlled international study, Clin. Neuropharmacol., 7, S316
Anderson, 1998, A meta-analysis of controlled trials comparing SSRIs in the treatment of depression, J. Psychopharmacol., 12, A20
Dowling, 1990, Fluoxetine: a comparative study with dothiepin, Irish J. Psychiatry, Spring, 3
1993, The treatment of depression in primary care, Effective Health Care Bull., 5, 1
Fawcett, 1989, Fluoxetine versus amitriptyline in adult out-patients with major depression, Curr. Ther. Res., 45, 821
Ginestet, 1989, Fluoxetine in endogenous depression melancholia versus clomipramine, Int. Clin. Psychopharmacol., 4, 37
Harris, 1991, Fluvoxamine versus amitriptyline in depressed hospital out-patients: A multicentre double-blind comparative trial, Br. J. Clin. Res., 2, 89
Hutchinson, 1991, A double blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients, Br. J. Clin. Res., 2, 43
Masco, 1985, Double-blind comparison of fluoxetine and amitriptyline in the treatment of major depressive illness, Adv. Ther., 2, 275
Pakesch, 1991, Depressive syndrome in a clinical trial with private practitioners. [German] OT – Wirkung und Sicherheit von Fluoxetin versus Clomipramin bei ambulanten Patienten mit einem depressiven Syndrom in einer klinischen Prufung bei niedergelassenen Arzten, Wien. Klin. Wochenschr., 103, 176
Pélicier, 1993, Etude multicentrique en double aveugle comparant l’efficacité et la tolerance de la paroxetine et de la clomipramine dans la dépression réactionnelle du sujet âgé, L’Encéphale, XIX, 257
Peters, 1990, Therapy of depression in the psychiatrist’s office – A double-blind multicenter study, Nervenheilkunde, 9, 28
Remick, 1989, A comparison between fluoxetine and doxepin in depressed patients, Curr. Ther. Res., 46, 842
Taneri, 1989, Fluoxetine versus nomifensine in out-patients with neurotic or reactive depression disorder, Int. Clin. Psychopharmacol., 4, 56

Sorted by citations

PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,372
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
Anderson, I. M., Ferrier, I. N., Baldwin, R., Cowen, P. J., Howard, L. M., Lewis, G., Matthews, K., McAllister-Williams, H., Peveler, R. C., Scott, J. L., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 909
Self-citation
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Lithium, a widely supported and used augmentation agent, is found to be more effective than placebo in augmentation of TCAs, SSRIs and other antidepressants (Bauer et al., 2000; Crossley and Bauer, 2007).”
BackgroundInfluential
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citation
Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors
Bymaster, F. P. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 725
The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
X-ray structure of dopamine transporter elucidates antidepressant mechanism
Penmatsa, A., Wang, K. H., & Gouaux, E. (2013) · Nature · doi:10.1038/nature12533 · Cited by 618
A Dose-Ranging Study of the Effects of Ethyl-Eicosapentaenoate in Patients With Ongoing Depression Despite Apparently Adequate Treatment With Standard Drugs
Peet, M., & Horrobin, D. F. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.913 · Cited by 615
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988–2010
Charlesworth, C. J., Smit, E., Lee, D. S. H., Alramadhan, F., & Odden, M. C. (2015) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv013 · Cited by 570
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 569
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis
Smith, D. D., Dempster, C., Glanville, J., Freemantle, N., & Anderson, I. M. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.180.5.396 · Cited by 538
Self-citation
Treatment and prevention of depression
Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002) · Psychological Science in the Public Interest · doi:10.1111/1529-1006.00008 · Cited by 511
Sertraline versus other antidepressive agents for depression
Cipriani, A., Ferla, T. L., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R. C., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 512
Quality of life in patients with multiple sclerosis
Janardhan, V., & Bakshi, R. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00312-x · Cited by 489
The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome
Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N., Rigby, C., Thompson, D., & Tomenson, B. (2003) · Gastroenterology · doi:10.1053/gast.2003.50055 · Cited by 443
The Medical Management of Depression
Mann, J. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050730 · Cited by 431
Neurobiology of depression: an integrated view of key findings
Maletic, V., Robinson, M., Oakes, T. M. M., Iyengar, S., Ball, S. G., & Russell, J. D. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01602.x · Cited by 414
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update
Spina, E., Santoro, V., & D’Arrigo, C. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80047-1 · Cited by 362
Hot flushes
Stearns, V., Ullmer, L., López, J. F., Smith, Y. R., Isaacs, C. J., & Hayes, D. F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11774-0 · Cited by 358
Obsessive-compulsive disorder
Stein, D. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09620-4 · Cited by 352
Meta-analytical studies on new antidepressants
Anderson, I. M. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.161 · Cited by 350
Self-citation
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 342
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Sertraline versus other antidepressive agents for depression
Cipriani, A., Ferla, T. L., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R. C., McGuire, H., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub2 · Cited by 323
Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
The burden of severe depression: A review of diagnostic challenges and treatment alternatives
Nemeroff, C. B. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.008 · Cited by 301
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Kennedy, S. H., & Emsley, R. A. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.002 · Cited by 300
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch, M. H., & Hannestad, J. O. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.100 · Cited by 303
Association of Low Bone Mineral Density With Selective Serotonin Reuptake Inhibitor Use by Older Men
Haney, E. M. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1246 · Cited by 286
Serotonin 5-HT2C Receptors as a Target for the Treatment of Depressive and Anxious States: Focus on Novel Therapeutic Strategies
Millan, M. J. (2005) · Therapies · doi:10.2515/therapie:2005065 · Cited by 296
Treatment of mood disorders
Nemeroff, C. B., & Owens, M. J. (2002) · Nature Neuroscience · doi:10.1038/nn943 · Cited by 284
Screening for Depression in Adult Patients in Primary Care Settings: A Systematic Evidence Review
O’Connor, E., Whitlock, E. P., Beil, T. L., & Gaynes, B. N. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-11-200912010-00007 · Cited by 279
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
Detke, M. J., Wiltse, C. G., Mallinckrodt, C. H., McNamara, R. K., Demitrack, M. A., & Bitter, I. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.01.002 · Cited by 285
Clashing diagnostic approaches: DSM-ICD versus RDoC
Lilienfeld, S. O., & Treadway, M. T. (2016) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-021815-093122 · Cited by 275
Amitriptyline for depression
Guaiana, G., Barbui, C., & Hotopf, M. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004186.pub2 · Cited by 273
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder
Olié, J., & Kasper, S. F. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007766 · Cited by 261
The role of monoamines in the actions of established and “novel” antidepressant agents: a critical review
Millan, M. J. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.038 · Cited by 260
Fluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 255
The role of the brain reward system in depression
Naranjo, C. A., Tremblay, L. K., & Busto, U. E. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00156-7 · Cited by 245
Side effects of antidepressants during long-term use in a naturalistic setting
Bet, P. M., Hugtenburg, J. G., Penninx, B. W. J. H., & Hoogendijk, W. J. G. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.001 · Cited by 239
Escitalopram Therapy for Major Depression and Anxiety Disorders
Baldwin, D. S., Reines, E. H., Guiton, C., & Weiller, E. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k089 · Cited by 228
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis
Kennedy, S. H., Andersen, H. F., & Lam, R. W. M. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0615 · Cited by 217
Tolerability and adherence issues in antidepressant therapy
Masand, P. S. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80220-5 · Cited by 215
Antidepressants for treating depression in dementia
Bains, J., Birks, J., & Dening, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944 · Cited by 214
The Burden of Major Depression Avoidable by Longer-term Treatment Strategies
Vos, T., Haby, M. M., Barendregt, J. J., Kruijshaar, M., Corry, J., & Andrews, G. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1097 · Cited by 213
Pharmacology of antidepressants
Richelson, E. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.5.511 · Cited by 210
Monoamine Transporter Gene Polymorphisms and Antidepressant Response in Koreans With Late-Life Depression
Kim, H. R., Lim, S., Kim, S., Kim, J., Chang, Y. H., Carroll, B. J., & Kim, D. K. (2006) · JAMA · doi:10.1001/jama.296.13.1609 · Cited by 202
Positive Spillovers and Free Riding in Advertising of Prescription Pharmaceuticals: The Case of Antidepressants
Shapiro, B. T. (2017) · Journal of Political Economy · doi:10.1086/695475 · Cited by 202
Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs
Millan, M. J. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.039 · Cited by 200
Exposure to Tricyclic and Selective Serotonin Reuptake Inhibitor Antidepressants and the Risk of Hip Fracture
Hubbard, R. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg114 · Cited by 199
Antidepressants for depression in physically ill people
Rayner, L., Price, A. C., Evans, A., Valsraj, K. M., Higginson, I. J., & Hotopf, M. H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007503.pub2 · Cited by 195
Relative efficacy of psychotherapy and combined therapy in the treatment of depression: A meta-analysis
de Maat, S. M., Dekker, J., Schoevers, R. A., & de Jonghe, F. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2006.10.008 · Cited by 192
A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples
Prado, C. E., Watt, S., & Crowe, S. F. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9369-5 · Cited by 188
Prescribing patterns of antidepressants in Europe: results from the factors influencing depression endpoints research (FINDER) study
Bauer, M., Monz, B. U., Montejo, A. L., Quail, D., Dantchev, N., Demyttenaere, K., Garcia-Cebrian, A., Grassi, L., Perahia, D. G. S., Reed, C., et al. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2007.11.001 · Cited by 186
Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression
Uher, R., Maier, W., Hauser, J., Marušič†, A., Schmael, C., Mors, O. N., Henigsberg, N., Souery, D., Placentino, A., Rietschel, M., et al. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.057554 · Cited by 186
DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS
SAFER, D. J. (2002) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200209000-00002 · Cited by 180
Public attitudes toward depression and help-seeking in four European countries baseline survey prior to the OSPI-Europe intervention
Coppens, E., Audenhove, C. V., Scheerder, G., Arensman, E., Coffey, C., Costa, S., Koburger, N., Gottlebe, K., Gusmão, R. M., O’Connor, R. C., et al. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.013 · Cited by 178
Structural biology of solute carrier (SLC) membrane transport proteins
Bai, X., Moraes, T. F., & Reithmeier, R. A. F. (2017) · Molecular Membrane Biology · doi:10.1080/09687688.2018.1448123 · Cited by 175
A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: Do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?
Walker, F. R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.10.002 · Cited by 175
Antidepressants for treating depression in dementia
Dudas, R., Malouf, R., McCleery, J., & Dening, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944.pub2 · Cited by 175
The Efficacy of Adjunctive N-Acetylcysteine in Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Trial
Berk, M., Dean, O. M., Cotton, S. M., Jeavons, S., Tanious, M., Kohlmann, K., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08454 · Cited by 172
Efficacy of treatment in older depressed patients: A systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants
Kok, R. M., Nolen, W. A., & Heeren, T. J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.02.036 · Cited by 167
Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression.
Logan, A. C. (2003) · PubMed · Cited by 163
Clinical Guidelines for the Treatment of Depressive Disorders IV. Medications and Other Biological Treatments
Kennedy, S. H., Lam, R. W. M., Cohen, N. L., Ravindran, A. V., & The CANMAT Depression Work Group (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674372001460101004 · Cited by 223
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M. A., Sloan, D. M., & Thase, M. E. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.027 · Cited by 161
Paroxetine Prevents Loss of Nigrostriatal Dopaminergic Neurons by Inhibiting Brain Inflammation and Oxidative Stress in an Experimental Model of Parkinson’s Disease
Chung, Y. C., Kim, S. R., & Jin, B. K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000208 · Cited by 159
Tolerability issues during long-term treatment with antidepressants
Cassano, P., & Fava, M. (2004) · Annals of Clinical Psychiatry · doi:10.1080/10401230490281618 · Cited by 154
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression
Stahl, S. M., Entsuah, R., & Rudolph, R. L. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01425-7 · Cited by 150
Advances in small molecules promoting neurotrophic function
PRICE, R., MILNE, S., SHARKEY, J., & MATSUOKA, N. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.005 · Cited by 148
Evidence-Based Practices in Geriatric Mental Health Care
Bartels, S. J., Citters, A. D. V., Oxman, T. E., Schneider, L. S., Areán, P. A., Alexopoulos, G. S., & Jeste, D. V. (2002) · Psychiatric Services · doi:10.1176/appi.ps.53.11.1419 · Cited by 146
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder
Cutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 156
Prevalence and outcome of partial remission in depression
Tranter, R., O’Donovan, C., Chandarana, P. C., & Kennedy, S. H. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0242 · Cited by 145
Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders
Mendlewicz, J. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970802503086 · Cited by 143
General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction
Tata, L. J., West, J., Smith, C., Farrington, P., Card, T. R., Smeeth, L. L., & Hubbard, R. (2005) · Heart · doi:10.1136/hrt.2004.037457 · Cited by 143
Treatment of menopausal symptoms: what shall we do now?
Hickey, M., Davis, S. R., & Sturdee, D. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66519-1 · Cited by 145
Escitalopram in the treatment of major depressive disorder: A meta-analysis
Kennedy, S. H., Andersen, H. F., & Thase, M. E. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802622726 · Cited by 143
Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis
Mészáros, Á., Czobor, P., Bálint, S., Komlósi, S., Simon, V., & Bitter, I. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990198 · Cited by 138
Brain Systems Underlying Susceptibility to Helplessness and Depression
Shumake, J., & Gonzalez-Lima, F. (2003) · Behavioral and Cognitive Neuroscience Reviews · doi:10.1177/1534582303259057 · Cited by 139
Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats
Kitaichi, Y., Inoue, T., Nakagawa, S., Boku, S., Kakuta, A., Izumi, T., & Koyama, T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.08.026 · Cited by 132
Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
Mallinckrodt, C. H., Watkin, J. G., Liu, C., Wohlreich, M. M., & Raskin, J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-1 · Cited by 134
The Depression Treatment Cascade in Primary Care: A Public Health Perspective
Pence, B. W., O’Donnell, J. K., & Gaynes, B. N. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0274-y · Cited by 133
Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans
Neill, J. C., Harte, M., Haddad, P. M., Lydall, E. S., & Dwyer, D. M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.011 · Cited by 133
Fluoxetine versus other types of pharmacotherapy for depression
Cipriani, A., Brambilla, P., Furukawa, T. A., Geddes, J. R., Gregis, M., Hotopf, M. H., Malvini, L., & Barbui, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub2 · Cited by 146
Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms
Sir, A., D'Souza, R. F., Uguz, S., George, T., Vahip, S., Hopwood, M., Martin, A. J., Lam, W., & Burt, T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1015 · Cited by 129
The Deficit of Pain Inhibition in Fibromyalgia Is More Pronounced in Patients With Comorbid Depressive Symptoms
de Souza, J. B., Potvin, S., Goffaux, P., Charest, J., & Marchand, S. (2009) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e318183cfa4 · Cited by 129
Depression and the risk for dementia
Kessing, L. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328356c368 · Cited by 130
Effect of various classes of antidepressants in behavioral paradigms of despair
Kulkarni, S. K., & Dhir, A. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.05.002 · Cited by 126
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M. A., Sloan, D. M., & Thase, M. E. (2010) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.8.4.foc592 · Cited by 126
Efficacy markers in depression
Harmer, C. J., Cowen, P. J., & Goodwin, G. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110367722 · Cited by 122
A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
Fornaro, M., Prestía, D., Colicchio, S., & Perugi, G. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246227 · Cited by 120
Relative efficacy of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis
de Maat, S. C. M., Dekker, J., Schoevers, R. A., & de Jonghe, F. E. R. E. R. (2006) · Psychotherapy Research · doi:10.1080/10503300600756402 · Cited by 123
Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression
Souery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Bollen, J., Demyttenaere, K., Kasper, S. F., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182228619 · Cited by 118
Motor activity and autonomic cardiac functioning in major depressive disorder
Volkers, A. C. W. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00066-6 · Cited by 116
LC–MS/MS method for the determination of nine antidepressants and some of their main metabolites in oral fluid and plasma
de Castro, A., Concheiro, M., Quintela, O., Cruz, A., & López‐Rivadulla, M. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.05.024 · Cited by 117
Psychosocial and pharmacological interventions for depressed adults in primary care: A critical review
Wolf, N. J., & Hopko, D. R. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.04.004 · Cited by 116
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo‐controlled clinical trials
Hudson, J. I., Wohlreich, M. M., Kajdasz, D. K., Mallinckrodt, C. H., Watkin, J. G., & Martynov, O. V. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.696 · Cited by 116
Cost-Effectiveness of Cognitive–Behavioural Therapy and Drug Interventions for Major Depression
Vos, T., Corry, J., Haby, M. M., Carter, R., & Andrews, G. (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01652.x · Cited by 114
Selective Serotonin Reuptake Inhibitors
Mozayani, M. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-222-9_6 · Cited by 113
Pseudobulbar affect: prevalence and management
Simmons, Z., & Ahmed, A. (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s53906 · Cited by 112

Authors: Anderson, I. M.
Affiliations: University of Manchester (GB)
Corresponding author: Anderson, Ian M.
ORCID: Anderson, Ian M.
Venue: Journal of Affective Disorders
Publisher: Elsevier BV
Published: 2000-04
Volume: 58
Issue: 1
Pages: 19-36
ISSN: 0165-0327 (ISSN-L)
DOI: 10.1016/s0165-0327(99)00092-0
OpenAlex: W2101963851
Cited by: 940
References: 159
Citations by year: 2026: 9 · 2025: 11 · 2024: 29 · 2023: 22 · 2022: 19 · 2021: 13 · 2020: 175 · 2019: 18 · 2018: 26 · 2017: 34 · 2016: 23 · 2015: 35 · 2014: 44 · 2013: 36 · 2012: 52
FWCI: 4.28
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Affective Disorders (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords: selective serotonin reuptake inhibitors, tricyclic antidepressants, depression, antidepressant efficacy, antidepressant tolerability, treatment discontinuation, adverse drug reactions, amitriptyline, fluvoxamine, dothiepin, inpatient care, publication bias
MeSH terms: Antidepressive Agents, Tricyclic, Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks